Xenetic Biosciences (XBIO) Net Cash Flow (2023 - 2025)
Xenetic Biosciences (XBIO) has disclosed Net Cash Flow for 6 consecutive years, with -$658247.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Net Cash Flow fell 43.4% year-over-year to -$658247.0, compared with a TTM value of -$2.7 million through Sep 2025, up 7.44%, and an annual FY2024 reading of -$2.8 million, up 31.52% over the prior year.
- Net Cash Flow was -$658247.0 for Q3 2025 at Xenetic Biosciences, down from -$383830.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at -$383830.0 in Q2 2025 and bottomed at -$1.3 million in Q2 2023.
- Average Net Cash Flow over 3 years is -$815969.6, with a median of -$793027.0 recorded in 2023.
- The sharpest move saw Net Cash Flow skyrocketed 58.62% in 2024, then crashed 43.4% in 2025.
- Year by year, Net Cash Flow stood at -$793027.0 in 2023, then grew by 15.01% to -$673992.0 in 2024, then increased by 2.34% to -$658247.0 in 2025.
- Business Quant data shows Net Cash Flow for XBIO at -$658247.0 in Q3 2025, -$383830.0 in Q2 2025, and -$1.0 million in Q1 2025.